NASDAQ: RGEN · Life Sciences · 7 alerts · CIK 730272
Share price
$162.78Close, Nov 16
Market cap
$10.4B
Shares outstanding
63.92MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Repligen Corp filings on SEC EDGAR ↗
Repligen reported a net loss of $38.4 million for the third quarter of 2026, primarily driven by a $41.2 million intangible asset impairment charge. Despite the loss, total revenue grew to $209.3 million for the quarter, up from $188.8 million in the prior year period, while cash provided by operating activities increased to $104.2 million for the first nine months of the year.
Repligen Corporation reported record third-quarter 2026 revenue of $209.3 million, representing 11% reported and 12.5% organic growth. The company also announced the completion of its BioLife Solutions acquisition in October and raised its full-year 2026 revenue guidance to a range of $844-$852 million.
“We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End-market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book.”
Olivier Loeillot, President and Chief Executive Officer
“The completion of the BioLife acquisition in October marks a significant milestone for Repligen, and integration is progressing well. Early customer feedback has been very encouraging, and we have already taken actions to realize a sizable portion of our expected operating expense synergies. Our strong year-to-date performance, continued order momentum and the addition of BioLife give us confidence to raise our full-year guidance again.”
Olivier Loeillot, President and Chief Executive Officer